CompletedPhase 4

Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists

NCT00443872

What is this trial?

Generating plain-language summary...

Generating eligibility summary...

Summarizing study design...

Primary location

University of California - Irvine

Irvine, California, United States

+16 additional locations

Save this trial

University of California - IrvineIrvine, California, United States
Coastal Neurological Medical Group, IncLa Jolla, California, United States
University of Southern CaliforniaLos Angeles, California, United States
The Parkinson's InstituteSunnyvale, California, United States
Parkinson's Disease and Movement Disorder Center of Boca RatonBoca Raton, Florida, United States
University of South FloridaTampa, Florida, United States
Methodist Plaza Speciality ClinicDes Moines, Iowa, United States
University of Kansas Medical CenterKansas City, Kansas, United States
Ochsner Clinic FoundationNew Orleans, Louisiana, United States
Beth Israel Deaconess Medical CenterBoston, Massachusetts, United States
Harvard Vanguard Medical AssociatesBoston, Massachusetts, United States
Henry Ford Health Center - Franklin PointeSouthfield, Michigan, United States
Struthers Parkinson's CenterGolden Valley, Minnesota, United States
University of ToledoToledo, Ohio, United States
NeuroHealth Parkinson Disease and Movement Disorder CenterWarwick, Rhode Island, United States
Neurology Specialists DallasDallas, Texas, United States
ETMC Neurological InstituteTyler, Texas, United States